Hexarelin vs LL-37
Updated July 27, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Hexarelin and LL-37 (also searched as LL-37 vs Hexarelin) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Hexarelin centers on muscle, while LL-37 leans toward healing. On indexed research, Hexarelin is ahead (Hexarelin: 5 studies, Human evidence; LL-37: 5, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Hexarelin is strongest for muscle; LL-37 for healing.
- •Evidence: Hexarelin Human evidence (5 studies) vs LL-37 Human evidence (5).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
Hexarelin vs LL-37: side-by-side
| Metric | Hexarelin | LL-37 |
|---|---|---|
| Class | GH | Immune |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human evidence | Human evidence |
| Studies indexed | 5 | 5 |
| Research level | Well Studied | Well Studied |
| Strongest effect | Muscle & body comp | Healing & recovery |
| Healing & recovery | 1.0 | 4.0▲ |
| Muscle & body comp | 4.0▲ | 0.0 |
| Metabolic & appetite | 3.0▲ | 0.0 |
| Neuro & mood | 2.0▲ | 0.0 |
| Sleep & circadian | 1.0▲ | 0.0 |
| Inflammation & immune | 2.0 | 4.0▲ |
| Skin & aesthetics | 2.0▲ | 0.0 |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Hexarelin | LL-37 |
|---|---|---|
| Mechanism | GHS-R agonist | Disrupts microbial membranes; modulates immune responses |
| Route | Subcutaneous injection | — |
| Half-life | ~2.5 hours | — |
| Time to peak | 30 min | — |
| Duration of action | ~6 hours | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Hexarelin?
### Hexarelin Summary Hexarelin is a synthetic hexapeptide that belongs to the growth hormone secretagogue (GHS) class, known for its ability to stimulate growth hormone release from the pituitary gland. It has been investigated for its potential therapeutic applications in various conditions, including muscle wasting and age-related decline in growth hormone levels.
Full Hexarelin profile, mechanism & studies →What is LL-37?
### LL-37 Summary LL-37 is a human cathelicidin antimicrobial peptide that plays a crucial role in the innate immune response, exhibiting antimicrobial, immunomodulatory, and wound healing properties. Its diverse functions make it a subject of interest in various fields of biomedical research.
Full LL-37 profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | LL-37 | 4.0/5 effect signal |
| Muscle | Hexarelin | 4.0/5 effect signal |
| Metabolic | Hexarelin | 3.0/5 effect signal |
| Neuro | Hexarelin | 2.0/5 effect signal |
| Sleep | Hexarelin | 1.0/5 effect signal |
| Inflammation | LL-37 | 4.0/5 effect signal |
| Skin | Hexarelin | 2.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Hexarelin and LL-37?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Hexarelin vs LL-37: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Hexarelin has 5 approved studies indexed (Human evidence), and LL-37 has 5 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Hexarelin or LL-37 better?
It depends on your goal. Hexarelin is strongest for muscle; LL-37 for healing. Hexarelin has more indexed studies (5). See the goal-by-goal breakdown above.
Is Hexarelin or LL-37 better for weight loss?
Hexarelin shows the stronger metabolic & appetite profile (3.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is Hexarelin or LL-37 better for muscle?
Hexarelin leads on the muscle & body-composition axis (4.0/5).
Which has more research, Hexarelin or LL-37?
Hexarelin has 5 approved studies indexed (Human evidence); LL-37 has 5 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack Hexarelin and LL-37?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Hexarelin vs LL-37?
Hexarelin: no community-reported effects logged yet. LL-37: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Hexarelin or LL-37 FDA-approved?
Hexarelin is a research-use compound and is not FDA-approved. LL-37 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is LL-37 better than Hexarelin?
For healing, LL-37 has the edge; for muscle, Hexarelin does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Hexarelin and LL-37 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 27, 2026.